SrasV1, PubMed, Curation, bibRecord, 000754

The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus.

Identifieur interne : 000754 ( PubMed/Curation ); précédent : 000753; suivant : 000755

The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus.

Auteurs : Calvin J. Gordon [Canada] ; Egor P. Tchesnokov [Canada] ; Joy Y. Feng [États-Unis] ; Danielle P. Porter [États-Unis] ; Matthias Götte [Canada]

Source :

The Journal of biological chemistry [ 1083-351X ] ; 2020.

RBID : pubmed:32094225

Descripteurs français

KwdFr :
- AMP (), AMP (analogues et dérivés), AMP (pharmacologie), ARN, Alanine (), Alanine (analogues et dérivés), Alanine (pharmacologie), Animaux, Antiviraux (), Antiviraux (pharmacologie), Cellules Sf9, Coronavirus (enzymologie), Coronavirus du syndrome respiratoire du Moyen-Orient (enzymologie), Ebolavirus (enzymologie), Expression des gènes, Inhibiteurs de la synthèse d'acide nucléique (), Inhibiteurs de la synthèse d'acide nucléique (pharmacologie), Protéines virales non structurales (génétique), RNA replicase (antagonistes et inhibiteurs), RNA replicase (génétique), Réplication virale ().
MESH :
- analogues et dérivés : AMP, Alanine.
- antagonistes et inhibiteurs : RNA replicase.
- enzymologie : Coronavirus, Coronavirus du syndrome respiratoire du Moyen-Orient, Ebolavirus.
- génétique : Protéines virales non structurales, RNA replicase.
- pharmacologie : AMP, Alanine, Antiviraux, Inhibiteurs de la synthèse d'acide nucléique.
- AMP, ARN, Alanine, Animaux, Antiviraux, Cellules Sf9, Expression des gènes, Inhibiteurs de la synthèse d'acide nucléique, Réplication virale.

English descriptors

KwdEn :
- Adenosine Monophosphate (analogs & derivatives), Adenosine Monophosphate (chemistry), Adenosine Monophosphate (pharmacology), Alanine (analogs & derivatives), Alanine (chemistry), Alanine (pharmacology), Animals, Antiviral Agents (chemistry), Antiviral Agents (pharmacology), Coronavirus (enzymology), Ebolavirus (enzymology), Gene Expression, Middle East Respiratory Syndrome Coronavirus (enzymology), Nucleic Acid Synthesis Inhibitors (chemistry), Nucleic Acid Synthesis Inhibitors (pharmacology), RNA, RNA Replicase (antagonists & inhibitors), RNA Replicase (genetics), Sf9 Cells, Viral Nonstructural Proteins (genetics), Virus Replication (drug effects).
MESH :
- chemical , analogs & derivatives : Adenosine Monophosphate, Alanine.
- chemical , antagonists & inhibitors : RNA Replicase.
- chemical , chemistry : Adenosine Monophosphate, Alanine, Antiviral Agents, Nucleic Acid Synthesis Inhibitors.
- chemical , genetics : RNA Replicase, Viral Nonstructural Proteins.
- chemical , pharmacology : Adenosine Monophosphate, Alanine, Antiviral Agents, Nucleic Acid Synthesis Inhibitors.
- drug effects : Virus Replication.
- enzymology : Coronavirus, Ebolavirus, Middle East Respiratory Syndrome Coronavirus.
- Animals, Gene Expression, RNA, Sf9 Cells.

Abstract

Antiviral drugs for managing infections with human coronaviruses are not yet approved, posing a serious challenge to current global efforts aimed at containing the outbreak of severe acute respiratory syndrome-coronavirus 2 (CoV-2). Remdesivir (RDV) is an investigational compound with a broad spectrum of antiviral activities against RNA viruses, including severe acute respiratory syndrome-CoV and Middle East respiratory syndrome (MERS-CoV). RDV is a nucleotide analog inhibitor of RNA-dependent RNA polymerases (RdRps). Here, we co-expressed the MERS-CoV nonstructural proteins nsp5, nsp7, nsp8, and nsp12 (RdRp) in insect cells as a part a polyprotein to study the mechanism of inhibition of MERS-CoV RdRp by RDV. We initially demonstrated that nsp8 and nsp12 form an active complex. The triphosphate form of the inhibitor (RDV-TP) competes with its natural counterpart ATP. Of note, the selectivity value for RDV-TP obtained here with a steady-state approach suggests that it is more efficiently incorporated than ATP and two other nucleotide analogs. Once incorporated at position i, the inhibitor caused RNA synthesis arrest at position i + 3. Hence, the likely mechanism of action is delayed RNA chain termination. The additional three nucleotides may protect the inhibitor from excision by the viral 3'-5' exonuclease activity. Together, these results help to explain the high potency of RDV against RNA viruses in cell-based assays.

DOI: 10.1074/jbc.AC120.013056
PubMed: 32094225

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000754

Links to Exploration step

pubmed:32094225

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus.</title>
<author><name sortKey="Gordon, Calvin J" sort="Gordon, Calvin J" uniqKey="Gordon C" first="Calvin J" last="Gordon">Calvin J. Gordon</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Alberta T6G 2E1, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Alberta T6G 2E1</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Tchesnokov, Egor P" sort="Tchesnokov, Egor P" uniqKey="Tchesnokov E" first="Egor P" last="Tchesnokov">Egor P. Tchesnokov</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Alberta T6G 2E1, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Alberta T6G 2E1</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Feng, Joy Y" sort="Feng, Joy Y" uniqKey="Feng J" first="Joy Y" last="Feng">Joy Y. Feng</name>
<affiliation wicri:level="2"><nlm:affiliation>Gilead Sciences, Inc., Foster City, California 94404.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
<wicri:cityArea>Gilead Sciences, Inc., Foster City</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Porter, Danielle P" sort="Porter, Danielle P" uniqKey="Porter D" first="Danielle P" last="Porter">Danielle P. Porter</name>
<affiliation wicri:level="2"><nlm:affiliation>Gilead Sciences, Inc., Foster City, California 94404.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
<wicri:cityArea>Gilead Sciences, Inc., Foster City</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Gotte, Matthias" sort="Gotte, Matthias" uniqKey="Gotte M" first="Matthias" last="Götte">Matthias Götte</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Alberta T6G 2E1, Canada gotte@ualberta.ca.</nlm:affiliation>
<country wicri:rule="url">Canada</country>
<wicri:regionArea>Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Alberta T6G 2E1</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32094225</idno>
<idno type="pmid">32094225</idno>
<idno type="doi">10.1074/jbc.AC120.013056</idno>
<idno type="wicri:Area/PubMed/Corpus">000754</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000754</idno>
<idno type="wicri:Area/PubMed/Curation">000754</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000754</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus.</title>
<author><name sortKey="Gordon, Calvin J" sort="Gordon, Calvin J" uniqKey="Gordon C" first="Calvin J" last="Gordon">Calvin J. Gordon</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Alberta T6G 2E1, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Alberta T6G 2E1</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Tchesnokov, Egor P" sort="Tchesnokov, Egor P" uniqKey="Tchesnokov E" first="Egor P" last="Tchesnokov">Egor P. Tchesnokov</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Alberta T6G 2E1, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Alberta T6G 2E1</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Feng, Joy Y" sort="Feng, Joy Y" uniqKey="Feng J" first="Joy Y" last="Feng">Joy Y. Feng</name>
<affiliation wicri:level="2"><nlm:affiliation>Gilead Sciences, Inc., Foster City, California 94404.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
<wicri:cityArea>Gilead Sciences, Inc., Foster City</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Porter, Danielle P" sort="Porter, Danielle P" uniqKey="Porter D" first="Danielle P" last="Porter">Danielle P. Porter</name>
<affiliation wicri:level="2"><nlm:affiliation>Gilead Sciences, Inc., Foster City, California 94404.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
<wicri:cityArea>Gilead Sciences, Inc., Foster City</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Gotte, Matthias" sort="Gotte, Matthias" uniqKey="Gotte M" first="Matthias" last="Götte">Matthias Götte</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Alberta T6G 2E1, Canada gotte@ualberta.ca.</nlm:affiliation>
<country wicri:rule="url">Canada</country>
<wicri:regionArea>Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Alberta T6G 2E1</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series><title level="j">The Journal of biological chemistry</title>
<idno type="eISSN">1083-351X</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adenosine Monophosphate (analogs & derivatives)</term>
<term>Adenosine Monophosphate (chemistry)</term>
<term>Adenosine Monophosphate (pharmacology)</term>
<term>Alanine (analogs & derivatives)</term>
<term>Alanine (chemistry)</term>
<term>Alanine (pharmacology)</term>
<term>Animals</term>
<term>Antiviral Agents (chemistry)</term>
<term>Antiviral Agents (pharmacology)</term>
<term>Coronavirus (enzymology)</term>
<term>Ebolavirus (enzymology)</term>
<term>Gene Expression</term>
<term>Middle East Respiratory Syndrome Coronavirus (enzymology)</term>
<term>Nucleic Acid Synthesis Inhibitors (chemistry)</term>
<term>Nucleic Acid Synthesis Inhibitors (pharmacology)</term>
<term>RNA</term>
<term>RNA Replicase (antagonists & inhibitors)</term>
<term>RNA Replicase (genetics)</term>
<term>Sf9 Cells</term>
<term>Viral Nonstructural Proteins (genetics)</term>
<term>Virus Replication (drug effects)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>AMP ()</term>
<term>AMP (analogues et dérivés)</term>
<term>AMP (pharmacologie)</term>
<term>ARN</term>
<term>Alanine ()</term>
<term>Alanine (analogues et dérivés)</term>
<term>Alanine (pharmacologie)</term>
<term>Animaux</term>
<term>Antiviraux ()</term>
<term>Antiviraux (pharmacologie)</term>
<term>Cellules Sf9</term>
<term>Coronavirus (enzymologie)</term>
<term>Coronavirus du syndrome respiratoire du Moyen-Orient (enzymologie)</term>
<term>Ebolavirus (enzymologie)</term>
<term>Expression des gènes</term>
<term>Inhibiteurs de la synthèse d'acide nucléique ()</term>
<term>Inhibiteurs de la synthèse d'acide nucléique (pharmacologie)</term>
<term>Protéines virales non structurales (génétique)</term>
<term>RNA replicase (antagonistes et inhibiteurs)</term>
<term>RNA replicase (génétique)</term>
<term>Réplication virale ()</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Adenosine Monophosphate</term>
<term>Alanine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>RNA Replicase</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Adenosine Monophosphate</term>
<term>Alanine</term>
<term>Antiviral Agents</term>
<term>Nucleic Acid Synthesis Inhibitors</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>RNA Replicase</term>
<term>Viral Nonstructural Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Adenosine Monophosphate</term>
<term>Alanine</term>
<term>Antiviral Agents</term>
<term>Nucleic Acid Synthesis Inhibitors</term>
</keywords>
<keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>AMP</term>
<term>Alanine</term>
</keywords>
<keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>RNA replicase</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Virus Replication</term>
</keywords>
<keywords scheme="MESH" qualifier="enzymologie" xml:lang="fr"><term>Coronavirus</term>
<term>Coronavirus du syndrome respiratoire du Moyen-Orient</term>
<term>Ebolavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="enzymology" xml:lang="en"><term>Coronavirus</term>
<term>Ebolavirus</term>
<term>Middle East Respiratory Syndrome Coronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Protéines virales non structurales</term>
<term>RNA replicase</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>AMP</term>
<term>Alanine</term>
<term>Antiviraux</term>
<term>Inhibiteurs de la synthèse d'acide nucléique</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Gene Expression</term>
<term>RNA</term>
<term>Sf9 Cells</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>AMP</term>
<term>ARN</term>
<term>Alanine</term>
<term>Animaux</term>
<term>Antiviraux</term>
<term>Cellules Sf9</term>
<term>Expression des gènes</term>
<term>Inhibiteurs de la synthèse d'acide nucléique</term>
<term>Réplication virale</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Antiviral drugs for managing infections with human coronaviruses are not yet approved, posing a serious challenge to current global efforts aimed at containing the outbreak of severe acute respiratory syndrome-coronavirus 2 (CoV-2). Remdesivir (RDV) is an investigational compound with a broad spectrum of antiviral activities against RNA viruses, including severe acute respiratory syndrome-CoV and Middle East respiratory syndrome (MERS-CoV). RDV is a nucleotide analog inhibitor of RNA-dependent RNA polymerases (RdRps). Here, we co-expressed the MERS-CoV nonstructural proteins nsp5, nsp7, nsp8, and nsp12 (RdRp) in insect cells as a part a polyprotein to study the mechanism of inhibition of MERS-CoV RdRp by RDV. We initially demonstrated that nsp8 and nsp12 form an active complex. The triphosphate form of the inhibitor (RDV-TP) competes with its natural counterpart ATP. Of note, the selectivity value for RDV-TP obtained here with a steady-state approach suggests that it is more efficiently incorporated than ATP and two other nucleotide analogs. Once incorporated at position <i>i</i>
, the inhibitor caused RNA synthesis arrest at position <i>i</i>
 + 3. Hence, the likely mechanism of action is delayed RNA chain termination. The additional three nucleotides may protect the inhibitor from excision by the viral 3'-5' exonuclease activity. Together, these results help to explain the high potency of RDV against RNA viruses in cell-based assays.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32094225</PMID>
<DateCompleted><Year>2020</Year>
<Month>04</Month>
<Day>15</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>04</Month>
<Day>18</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1083-351X</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>295</Volume>
<Issue>15</Issue>
<PubDate><Year>2020</Year>
<Month>04</Month>
<Day>10</Day>
</PubDate>
</JournalIssue>
<Title>The Journal of biological chemistry</Title>
<ISOAbbreviation>J. Biol. Chem.</ISOAbbreviation>
</Journal>
<ArticleTitle>The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus.</ArticleTitle>
<Pagination><MedlinePgn>4773-4779</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1074/jbc.AC120.013056</ELocationID>
<Abstract><AbstractText>Antiviral drugs for managing infections with human coronaviruses are not yet approved, posing a serious challenge to current global efforts aimed at containing the outbreak of severe acute respiratory syndrome-coronavirus 2 (CoV-2). Remdesivir (RDV) is an investigational compound with a broad spectrum of antiviral activities against RNA viruses, including severe acute respiratory syndrome-CoV and Middle East respiratory syndrome (MERS-CoV). RDV is a nucleotide analog inhibitor of RNA-dependent RNA polymerases (RdRps). Here, we co-expressed the MERS-CoV nonstructural proteins nsp5, nsp7, nsp8, and nsp12 (RdRp) in insect cells as a part a polyprotein to study the mechanism of inhibition of MERS-CoV RdRp by RDV. We initially demonstrated that nsp8 and nsp12 form an active complex. The triphosphate form of the inhibitor (RDV-TP) competes with its natural counterpart ATP. Of note, the selectivity value for RDV-TP obtained here with a steady-state approach suggests that it is more efficiently incorporated than ATP and two other nucleotide analogs. Once incorporated at position <i>i</i>
, the inhibitor caused RNA synthesis arrest at position <i>i</i>
 + 3. Hence, the likely mechanism of action is delayed RNA chain termination. The additional three nucleotides may protect the inhibitor from excision by the viral 3'-5' exonuclease activity. Together, these results help to explain the high potency of RDV against RNA viruses in cell-based assays.</AbstractText>
<CopyrightInformation>© 2020 Gordon et al.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gordon</LastName>
<ForeName>Calvin J</ForeName>
<Initials>CJ</Initials>
<AffiliationInfo><Affiliation>Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Alberta T6G 2E1, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Tchesnokov</LastName>
<ForeName>Egor P</ForeName>
<Initials>EP</Initials>
<AffiliationInfo><Affiliation>Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Alberta T6G 2E1, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Feng</LastName>
<ForeName>Joy Y</ForeName>
<Initials>JY</Initials>
<AffiliationInfo><Affiliation>Gilead Sciences, Inc., Foster City, California 94404.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Porter</LastName>
<ForeName>Danielle P</ForeName>
<Initials>DP</Initials>
<AffiliationInfo><Affiliation>Gilead Sciences, Inc., Foster City, California 94404.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Götte</LastName>
<ForeName>Matthias</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Alberta T6G 2E1, Canada gotte@ualberta.ca.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Li Ka Shing Institute of Virology at University of Alberta, Edmonton, Alberta T6G 2E1, Canada.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>159507</GrantID>
<Agency>CIHR</Agency>
<Country>Canada</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>02</Month>
<Day>24</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>J Biol Chem</MedlineTA>
<NlmUniqueID>2985121R</NlmUniqueID>
<ISSNLinking>0021-9258</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019384">Nucleic Acid Synthesis Inhibitors</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C034477">RNA primers</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017361">Viral Nonstructural Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>3QKI37EEHE</RegistryNumber>
<NameOfSubstance UI="C000606551">remdesivir</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>415SHH325A</RegistryNumber>
<NameOfSubstance UI="D000249">Adenosine Monophosphate</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>63231-63-0</RegistryNumber>
<NameOfSubstance UI="D012313">RNA</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 2.7.7.48</RegistryNumber>
<NameOfSubstance UI="D012324">RNA Replicase</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>OF5P57N2ZX</RegistryNumber>
<NameOfSubstance UI="D000409">Alanine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000249" MajorTopicYN="N">Adenosine Monophosphate</DescriptorName>
<QualifierName UI="Q000031" MajorTopicYN="Y">analogs & derivatives</QualifierName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000409" MajorTopicYN="N">Alanine</DescriptorName>
<QualifierName UI="Q000031" MajorTopicYN="Y">analogs & derivatives</QualifierName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017934" MajorTopicYN="N">Coronavirus</DescriptorName>
<QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D029043" MajorTopicYN="N">Ebolavirus</DescriptorName>
<QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D065207" MajorTopicYN="N">Middle East Respiratory Syndrome Coronavirus</DescriptorName>
<QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019384" MajorTopicYN="N">Nucleic Acid Synthesis Inhibitors</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012313" MajorTopicYN="N">RNA</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012324" MajorTopicYN="N">RNA Replicase</DescriptorName>
<QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D061987" MajorTopicYN="N">Sf9 Cells</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017361" MajorTopicYN="N">Viral Nonstructural Proteins</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Ebola virus (EBOV)</Keyword>
<Keyword MajorTopicYN="Y">Middle East respiratory syndrome coronavirus (MERS–CoV)</Keyword>
<Keyword MajorTopicYN="Y">RNA chain termination</Keyword>
<Keyword MajorTopicYN="Y">RNA-dependent RNA polymerase (RdRp)</Keyword>
<Keyword MajorTopicYN="Y">SARS–CoV-2</Keyword>
<Keyword MajorTopicYN="Y">antiviral drug</Keyword>
<Keyword MajorTopicYN="Y">coronavirus</Keyword>
<Keyword MajorTopicYN="Y">drug development</Keyword>
<Keyword MajorTopicYN="Y">enzyme inhibitor</Keyword>
<Keyword MajorTopicYN="Y">nucleoside/nucleotide analog</Keyword>
<Keyword MajorTopicYN="Y">plus-stranded RNA virus</Keyword>
<Keyword MajorTopicYN="Y">positive-sense RNA virus</Keyword>
<Keyword MajorTopicYN="Y">remdesivir</Keyword>
<Keyword MajorTopicYN="Y">viral polymerase</Keyword>
<Keyword MajorTopicYN="Y">viral replicase</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>02</Month>
<Day>14</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2020</Year>
<Month>02</Month>
<Day>19</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>2</Month>
<Day>26</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>4</Month>
<Day>16</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>2</Month>
<Day>26</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32094225</ArticleId>
<ArticleId IdType="pii">AC120.013056</ArticleId>
<ArticleId IdType="doi">10.1074/jbc.AC120.013056</ArticleId>
<ArticleId IdType="pmc">PMC7152756</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Nat Biotechnol. 2004 Dec;22(12):1583-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15568020</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Trials. 2020 Jan 3;21(1):8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31900204</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Sci Transl Med. 2017 Jun 28;9(396):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28659436</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2018 Jan 9;115(2):E162-E171</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29279395</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Antiviral Res. 2019 Sep;169:104541</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31233808</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Sci Rep. 2017 Mar 06;7:43395</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28262699</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Biol Chem. 2008 Dec 5;283(49):34218-28</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18940786</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Viruses. 2019 Apr 04;11(4):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30987343</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>N Engl J Med. 2019 Dec 12;381(24):2293-2303</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31774950</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Antimicrob Agents Chemother. 2014 Aug;58(8):4875-84</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24841269</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>EMBO J. 1989 Dec 1;8(12):3867-74</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2555175</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2014 Sep 16;111(37):E3900-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25197083</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Curr Protoc Protein Sci. 2008 Feb;Chapter 5:Unit 5.20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18429060</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Sci Rep. 2018 Mar 5;8(1):3970</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29507309</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>PLoS Pathog. 2015 Jun 22;11(6):e1004995</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26098424</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 1999 Mar;73(3):2333-42</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9971816</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Med Chem. 2017 Mar 9;60(5):1648-1661</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28124907</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nat Commun. 2019 May 28;10(1):2342</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31138817</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>EMBO J. 2006 Oct 18;25(20):4933-42</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17024178</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>mBio. 2018 Mar 6;9(2):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29511076</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2020 Mar 24;117(12):6771-6776</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32054787</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>PLoS Pathog. 2018 Feb 9;14(2):e1006889</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29425244</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>PLoS Pathog. 2012;8(10):e1002980</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23093940</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Cell Rep. 2017 Oct 24;21(4):1063-1076</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29069588</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nature. 2016 Mar 17;531(7594):381-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26934220</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nat Commun. 2020 Jan 10;11(1):222</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31924756</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000754 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000754 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    PubMed
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:32094225
   |texte=   The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i   -Sk "pubmed:32094225" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a SrasV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus.

The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki